Active Surveillance for Limited GGNs

Fudan University

Status: Not yet enrolling

Conditions: Lung Ground-glass Opacities; Active Surveillance

Treatments: Procedure: Active surveillance

Study type: Observational

Funder types: Other

Identifiers

NCT06394037

ECTOP-1028

Details and patient eligibility

About

This study is a single-arm, multi-center, phase III trial conducted under the Eastern Cooperative Thoracic Oncoloy Project (ECTOP) . The primary objective of the study is to assess the 5-year overall survival of patients with one or two ground-glass opacities by employing an active surveillance approach rather than immediate surgical resection.

Full description

The trial aims to confirm the hypotheses that delaying surgery until GGO nodules exhibit progression or meet certain criteria offers a prognosis equivalent to those undergoing immediate surgical resection, potentially allowing many of these patients to avoid surgery altogether.

Enrollment: 387 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Patients eligible for enrollment in the study are required to meet all the following criteria.

1. Demonstrates the following on thin-section computed tomography (TSCT) scan:

   1. Presence of one or two GGNs (bilateral lesions are permitted).
   2. All lesions have remained stable without regression or enlargement for at least 3 months.
   3. The dominant lesion (the lesion with the largest maximum tumor diameter) has a maximum tumor diameter ≥0.6cm and ≤2cm.
   4. CTR ≤0.25 in lesions.
   5. No lymph node with a diameter >1cm in the mediastinal view.
   6. Not adjacent to the pleura in dominant lesion and no sign of pleural retraction in any lesions.

2. Has not previously undergo any anti-tumor drug or radiation therapy for the lung lesions.

3. Aged 18-75 years.

4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

5. Written informed consent.

Patients will be excluded if they meet any of the following criteria.

1. History of any prior malignancies within the past 5 years.
2. History of lung surgery.
3. History of interstitial pneumonia, pulmonary fibrosis or other severe pulmonary diseases.
4. Presence of severe or uncontrolled diseases that may possibly reduce the 10-year life expectancy.

Trial design

387 participants in 1 patient group

Observation

Description:

Active surveillance

Treatment:

Procedure: Active surveillance